Therapeutics News and Research

RSS

PRWP receives two new patents for Galectin-targeting compounds in the U.S., Australia

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that the Company has been granted two new patents, "Co-administration of a Polysaccharide with a Chemotherapeutic Agent for the Treatment of Cancer" in Australia and "Selectively Depolymerized Galactomannan Polysaccharide" in the United States.

23 Mar 2011

SGEN, Abbott enter collaboration agreement for ADC products

Seattle Genetics, Inc.today announced that it has entered into a collaboration agreement with Abbott under which Abbott will pay an upfront fee of $8 million for rights to utilize Seattle Genetics' antibody-drug conjugate technology with antibodies to a single oncology target.

23 Mar 2011

Genetic errors in women linked to increased risk of preeclampsia

Scientists have identified genetic errors in women with autoimmune diseases that increase the risk of preeclampsia, a potentially life-threatening condition that occurs in 10 percent of all pregnancies.

23 Mar 2011

Roundup: HHS Secretary's ability to waive Medicaid requirements; Kansas seeks more funding for disability programs

U.S. Health and Human Services Secretary Kathleen Sebelius has broad legal authority to waive Medicaid maintenance-of-effort requirements, according to a memo from the Congressional Research Service to the U.S. Senate Finance Committee.

23 Mar 2011

AstraZeneca, Senectus sign deal to identify compounds that trigger cancer cell ageing

Senectus Therapeutics has signed a deal to screen a selection of AstraZeneca's chemical compound library to identify those which trigger a key element of cancer cell ageing - called senescence.

23 Mar 2011

AACP to honor UW professor with Volwiler Research Achievement Award

The American Association of Colleges of Pharmacy will honor Sidney D. Nelson, Ph.D., from the University of Washington for his outstanding research and contributions to the field of pharmaceutical sciences.

22 Mar 2011

Rxi's new RNAi preclinical data to be presented at Keystone conference

RXi Pharmaceuticals Corporation, a recognized leader in RNA interference based therapeutic discovery and development, today announced that new preclinical data using proprietary self-delivering RNAi compounds, including RXI-109, will be presented at the Keystone Symposia's Mechanism and Biology of Silencing conference being held March 20-25, 2011 in Monterey, California.

22 Mar 2011

Cephalon to acquire Gemin X Pharmaceuticals

Cephalon, Inc. announced today that it has signed a definitive merger agreement under which it will acquire all of the outstanding capital stock of Gemin X Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing first-in-class cancer therapeutics, for $225 million cash on a cash-free, debt-free basis. Gemin X stockholders could also receive up to $300 million in cash payments upon the achievement of certain regulatory and sales milestones.

22 Mar 2011

Second US trial in HIV/AIDS lymphoma patients using Benitec’s ddRNAi technology

Benitec Limited (ASX:BLT), a company involved in RNA-based gene silencing for human therapeutics, announced that the City of Hope research hospital in Duarte, California is planning to initiate a second small Phase I/II study using Benitec’s DNA-directed RNA interference (ddRNAi) technology in lymphoma patients carrying the HIV virus. The aim of the study is to optimize the treatment by modifying a range of clinical parameters.

21 Mar 2011

Sarsia Seed provides follow-up funding for APIM Therapeutics

APIM Therapeutics AS, an early-stage Norwegian therapeutic company, is pursuing a novel drug approach with the ability to potentiate the action of a wide range of chemotherapeutic drugs currently used to treat several types of cancer.

21 Mar 2011

Intravenous Phenoxodiol-cisplatin combination well tolerated in platinum resistant ovarian cancer

Marshall Edwards, Inc., an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the publication of results from a Phase II clinical trial of intravenous Phenoxodiol in combination with cisplatin in women with platinum-resistant ovarian cancer.

21 Mar 2011

Echo Therapeutics fiscal 2010 net loss decreases to $4.1 million

Echo Therapeutics, Inc., a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced results for the year ended December 31, 2010.

21 Mar 2011

Nektar initiates dosing in NKTR-181 Phase 1 clinical study for treatment of pain

Nektar Therapeutics today announced that the first subjects were dosed in a new Phase 1 clinical study to evaluate NKTR-181, the company's next-generation opioid analgesic candidate. NKTR-181 is being developed to effectively treat pain while addressing the abuse liability and serious CNS side effects associated with currently available opioid therapies.

21 Mar 2011

United Therapeutics completes enrollment in FREEDOM-C(2) UT-15C study in pulmonary arterial hypertension

United Therapeutics Corporation announced today that enrollment in its FREEDOM-C(2) registration trial was completed on March 18, 2011.

21 Mar 2011

Tiny Locked Nucleic Acid-based compounds inhibit entire disease-associated microRNA families

A study published online in this week's Nature Genetics demonstrates that tiny Locked Nucleic Acid (LNA)-based compounds developed by Santaris Pharma A/S can inhibit entire disease-associated microRNA families. This provides a potential new approach for treating a variety of diseases including cancer, viral infections, cardiovascular and muscle diseases.

21 Mar 2011

$CTI commences pixantrone PIX-R trial in relapsed/refractory diffuse large B-cell lymphoma$

CTI commences pixantrone PIX-R trial in relapsed/refractory diffuse large B-cell lymphoma

Cell Therapeutics, Inc. today announced that it has initiated its randomized pivotal trial of pixantrone for the treatment of relapsed/refractory diffuse large B-cell lymphoma ("DLBCL").

21 Mar 2011

The Lancet publishes Oceana's Solesta injectable gel study results against fecal incontinence

Oceana Therapeutics, a global company focused on acquiring, developing and commercializing best-in-class specialty therapeutics, today announced the publication of results from a randomized-controlled clinical trial of the bulking agent, NASHA DX, a dextranomer suspended in stabilized, which was injected into the submucosa of the anal canal in patients with fecal incontinence.

19 Mar 2011

Quark Pharmaceuticals receives results from Phase 2 trial of PF-04523655 in patients with DME

Quark Pharmaceuticals, Inc., a pharmaceutical company engaged in the discovery and development of RNAi-based therapeutics, today announced that it has received results from a prospective randomized Phase 2 trial, the DEGAS study.

19 Mar 2011

Sage Bionetworks, AstraZeneca enter cancer research collaboration

Sage Bionetworks and AstraZeneca have initiated a collaboration to make new insights into certain cancers using advanced computational models of disease genetics. This deeper understanding of cancer will potentially help better match patients with appropriate treatments and might one day lead to new cancer therapeutics.

18 Mar 2011

MHA hosts two-day Long Term Care Business Summit at ARIA

Managed Health Care Associates, Inc., a leading health care service company focused on alternate site health care providers, is hosting its 8th Annual MHA Business Summit for Long Term Care Pharmacies and other Long Term Care stakeholders on March 17th-18th at ARIA at CityCenter in Las Vegas, Nevada.

18 Mar 2011

Therapeutics News and Research

PRWP receives two new patents for Galectin-targeting compounds in the U.S., Australia

SGEN, Abbott enter collaboration agreement for ADC products

Genetic errors in women linked to increased risk of preeclampsia

Roundup: HHS Secretary's ability to waive Medicaid requirements; Kansas seeks more funding for disability programs

AstraZeneca, Senectus sign deal to identify compounds that trigger cancer cell ageing

AACP to honor UW professor with Volwiler Research Achievement Award

Rxi's new RNAi preclinical data to be presented at Keystone conference

Cephalon to acquire Gemin X Pharmaceuticals

Second US trial in HIV/AIDS lymphoma patients using Benitec’s ddRNAi technology

Sarsia Seed provides follow-up funding for APIM Therapeutics

Intravenous Phenoxodiol-cisplatin combination well tolerated in platinum resistant ovarian cancer

Echo Therapeutics fiscal 2010 net loss decreases to $4.1 million

Nektar initiates dosing in NKTR-181 Phase 1 clinical study for treatment of pain

United Therapeutics completes enrollment in FREEDOM-C(2) UT-15C study in pulmonary arterial hypertension

Tiny Locked Nucleic Acid-based compounds inhibit entire disease-associated microRNA families

CTI commences pixantrone PIX-R trial in relapsed/refractory diffuse large B-cell lymphoma

The Lancet publishes Oceana's Solesta injectable gel study results against fecal incontinence

Quark Pharmaceuticals receives results from Phase 2 trial of PF-04523655 in patients with DME

Sage Bionetworks, AstraZeneca enter cancer research collaboration

MHA hosts two-day Long Term Care Business Summit at ARIA

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News